See the latest news and media coverage for CLS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Laser ablation systems for cancer care and neurosurgery
clinicallaser.seLast updated
In short: CLS joined US spinal cancer program, reported SEK 23 million order, completed rights issue
The firm registered the offering with Swedish regulators on August 31, 2026, and begins warrant trading in September. The transaction increases share capital to approximately SEK 4.75 million.
The issue was subscribed to 78.5 % and gives CLS capital to accelerate the Prism business. New shares increase share capital by approx. 1.6 million SEK.
The issue volume is SEK 39.5 million and is covered by guarantees totaling SEK 29 million, with proceeds to fund commercialization and partnership expansion.
The Board decided on a rights issue of units with preferential rights, covered by subscriptions and guarantees.
Clinical Laserthermia Systems, CLS, has received an order with a total value of approximately 23 million kronor for its neurosurgical Prism business from...
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today publishes its Year-end report for January - December 2025.Highlights of the Year-end...
CLSLund, Sweden - September 4th, 2025 - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") today announced that the U.S. Food and Drug Administration...
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces it will focus entirely on its successful neurosurgery business to drive...
Track CLS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CLS and other trending companies.
